<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574415</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012004</org_study_id>
    <nct_id>NCT03574415</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean</brief_title>
  <official_title>A Single-center, Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of DWP14012 in Healthy Japanese, Caucasian and Korean</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single and multiple ascending oral doses of
      DWP14012 in healthy Japanese, Caucasian and Korean subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">January 23, 2019</completion_date>
  <primary_completion_date type="Actual">January 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h</time_frame>
    <description>Maximum concentration of DWP14012</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss / Cmin,ss</measure>
    <time_frame>1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h</time_frame>
    <description>Maximum / Minimum concentration of DWP14012 at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h</time_frame>
    <description>Time of maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast / AUCinf</measure>
    <time_frame>1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h</time_frame>
    <description>Elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>Day 1</time_frame>
    <description>After single administration of the investigational products, 24hr gastric pH monitoring started.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>Day 7</time_frame>
    <description>After single administration of the investigational products, 24hr gastric pH monitoring started.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Japanese_DWP14012 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Amg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese_DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese_DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian_DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian_DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Korean_DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Korean_DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablets, orally, single and multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DWP14012 placebo-matching tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012</intervention_name>
    <description>DWP14012 tablets</description>
    <arm_group_label>Caucasian_DWP14012 Bmg</arm_group_label>
    <arm_group_label>Caucasian_DWP14012 Cmg</arm_group_label>
    <arm_group_label>Japanese_DWP14012 Amg</arm_group_label>
    <arm_group_label>Japanese_DWP14012 Bmg</arm_group_label>
    <arm_group_label>Japanese_DWP14012 Cmg</arm_group_label>
    <arm_group_label>Korean_DWP14012 Bmg</arm_group_label>
    <arm_group_label>Korean_DWP14012 Cmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>DWP14012 placebo-matching tablets</description>
    <arm_group_label>Caucasian_DWP14012 Bmg</arm_group_label>
    <arm_group_label>Caucasian_DWP14012 Cmg</arm_group_label>
    <arm_group_label>Japanese_DWP14012 Amg</arm_group_label>
    <arm_group_label>Japanese_DWP14012 Bmg</arm_group_label>
    <arm_group_label>Japanese_DWP14012 Cmg</arm_group_label>
    <arm_group_label>Korean_DWP14012 Bmg</arm_group_label>
    <arm_group_label>Korean_DWP14012 Cmg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult Caucasian or Japanese or Korean aged 19 to 50 (inclusive) years, at the
             time of screening.

          -  Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg/m2 (inclusive)
             at screening visit.

        Exclusion Criteria:

          -  Those who have clinical significant liver, kidney, nervous system, respiratory,
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or
             past history

          -  Those who have gastrointestinal diseases or past history of gastrointestinal diseases
             (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's
             disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of
             study drug, and those who have past history of gastrointestinal surgery (however,
             except simple appendectomy and herniotomy)

          -  Those who have been Helicobacter pylori positive

          -  Those whose plasma AST (SGOT) and ALT (SGPT) exceed 1.5 times to the upper limit of
             the normal range in screening including additional examinations prior to randomization

          -  Those who have anatomical disability in insertion and maintenance of pH meter catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

